Anaveon In Depth

Developing Tomorrow’s Treatments

Anaveon is well positioned to be a leader in the field of engineered IL-2 and therapeutic cytokines. We are an exciting company with a track record of bringing new therapeutics from preclinical concept into the clinical proof of concept. Our motivated team of immunologists have extensive experience and a commitment to delivering the power of cytokines to patients.
Anaveon Team

Anaveon’s mission is to transform cytokines into life-saving treatments. The Company was founded in 2017 by experts in cutting-edge immunology, who wanted to design and develop patient treatments that benefit society.

This remains our vision today. Anaveon is a biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. The team has the skills to make this vision a reality: we are committed to transforming immunological insights into life-saving therapies.

Others share our vision, and investors have backed Anaveon with funding of more than 36 million CHF (€34 million).

Our dedicated team of drug developers is already 15 strong and growing. Anaveon’s expert scientists have decades of experience in drug development. Their expertise and drive to deliver tangible results are what sets our company apart.

Since 2017, Anaveon has grown in size and strength.
The first drug we are taking into clinical trials is
ANV419 – a selective interleukin-2 (IL-2) receptor agonist which is a fusion protein of a highly specific anti-IL-2 antibody and IL-2. This immunotherapy is part of our unique pipeline that is aiming to bring life-saving treatments closer to the patients who need them.

Company Information Pack

Anaveon corporate deck

Discover Anaveon®

Read about Anaveon’s work towards our mission to transform cytokines into life-saving treatments. In this downloadable info package, you can find out more about the company, our team of dedicated experts, the drugs we are preparing to take into clinical trials, and the programs we have in the pipeline.

Want to know more?

To ask us a question, or find out about collaboration opportunities, email us at contact@anaveon.com.

Anaveon®’s pipeline based on engineered cytokines

Anaveon is exploiting the power of cytokines to orchestrate immune responses through safe and effective treatments for a variety of serious diseases. Our pipeline reflects this: we are developing
a unique no-alpha IL-2 portfolio with broad potential in tumor immunotherapy.

Discovery

Lead Optimization

Preclinical Development

Phase I/II

Phase1

  • ANV 419 Systemic no-alpha IL-2

Lead Optimization

  • ANV600 Target no-alpha IL-2

Discovery

  • Engineered      Cytokine
Anaveon is developing a unique no-alpha IL-2 portfolio with broad potential in tumor immunotherapy. We are using our expertise in cytokines to deliver new investigational therapies for diseases with immune etiopathology.

Therapeutic Areas

The programs in Anaveon’s pipeline have potential across a range of therapeutic areas.

Solid

tumors

Cytokine immunotherapies could be used to treat solid tumors, including melanoma, renal cell cancer and bladder cancer.

Hematological

malignancies

Cancers of the blood, bone marrow and lymph nodes are potential targets, including leukemia, lymphoma and myeloma.

Combination

therapy

The programs in Anaveon’s pipeline could be used in combination with checkpoint inhibitors, innate immunity agonists, targeted agents or depleting antibodies.

Combination with

cell therapies

In combination with cutting-edge cell therapies, Anaveon’s programs could offer new benefits for cancer patients.

Quick Facts

  • ANV419 is a fusion protein of IL-2 with an anti-IL-2 antibody
  • In vitro and in vivo, ANV419 selectively signals through the IL-2Rβ/γ and promotes the expansion of both NK and CD8+ T cells but not Tregs
  • ANV419 is currently in first human studies to determine the optimal dose for safety and efficacy
  • Development in multiple cancer indications are planned to be initiated in 2022

Competitive Advantage

ANV419 has already displayed exceptional safety in early clinical studies and non-human primates. It is selective by design: ANV419 only promotes the function of CD8+ T cells and NK cells as immune effector cells while sparing regulatory T cells. Therefore, it is a potential treatment for a range of cancer types.

Latest Publications

Anaveon publication 1

ANV419 is a novel CD122 selective IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T cell and NK cell stimulatory function in vitro and in vivo

SITC Annual Meeting. 2020 Nov 9-14

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human Interleukin-2

Sci Transl Med. 2016 Nov 30;8(367):367ra166.

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms

 

Immunity. 2015 May 19;42(5):815-25

Start your journey with Anaveon® today

News